Boehringer Ingelheim (Canada) Ltd. receives approval for Metacam^®for Swine for relief of post-operative pain associated with soft tissue surgery such as castration

Burlington, Canada, September 7, 2016 - Boehringer Ingelheim has obtained approval for Metacam^®for Swine (active ingredient: meloxicam 5 mg/mL) with a new indication for the relief of post-operative pain associated with minor soft tissue surgery such as castration in pigs.

The marketing authorization was granted based on a large body of evidence for the efficacy of Metacam generated earlier by the Faculty of Veterinary Medicine at the Ludwig-Maximilians-University in Munich, Germany1. It demonstrated that Metacam administered at 0.4 mg/kg bodyweight prior to the castration of less than seven day old piglets had a significant impact on blood cortisol levels, a biochemical marker for the neuro endocrine reaction of the body to stress and pain. The study also demonstrated quicker alleviation of clinical symptoms and faster return to normal behaviour in piglets which received Metacam in comparison to animals which were not given analgesia.

Metacam^® for Swine is a non-steroidal anti-inflammatory drug of the oxicam class. It is a potent NSAID given as a single injection of 0.4mg/kg bodyweight (0.1mL/1.25 kg) by the IM route. Metacam^® for Swine should be administered 30 minutes before minor soft tissue surgery such as castration, and has a 5-day slaughter withdrawal for pigs.

For more information about Metacam^® for Swine, contact your veterinarian, or e-mail Eldon Hartwick with Boehringer Ingelheim (Canada) Ltd. at eldon.hartwick@boehringer-ingelheim.com.

About Boehringer Ingelheim Animal Health
Boehringer Ingelheim Animal Health is committed to fostering the health and well-being of mankind by promoting the emotional and physical benefits arising from the human animal bond. It has been providing solutions for the prevention and treatment of diseases in animals for almost 60 years.

About Boehringer Ingelheim (Canada) Ltd.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of more than 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of its net sales.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.

For more information please visit www.boehringer-ingelheim.ca.

Merry Garbutt
Corporate Communications
Boehringer Ingelheim (Canada) Ltd.
Email: merry.garbutt@boehringer-ingelheim.com
Phone: (905) 631-4531